分组1 - Delcath Systems Inc reported a significant increase in share price, rising 14.2% to $13.66 in pre-market trading following the announcement of preliminary third quarter 2025 financial results [1] - The company's Phase 2 CHOPIN study achieved its primary endpoint, demonstrating that PHP plus immunotherapy extended median progression-free survival (PFS) to 12.8 months, compared to 8.3 months previously [1] 分组2 - Beyond Meat Inc saw a substantial gain of 76.6%, reaching $1.14 in pre-market trading after a 24% surge on the previous Friday [4] - FGI Industries Ltd experienced a 64.1% increase to $7.81 in pre-market trading [4] - Celcuity Inc surged 44.3% to $75.00 following the announcement of Phase 3 VIKTORIA-1 data [4] - Rani Therapeutics Holdings Inc's shares jumped 32.5% to $2.18 after a collaboration agreement with Chugai Pharmaceutical and an oversubscribed $60.3 million private placement [4] 分组3 - Exelixis Inc's shares fell 8.3% to $36.00 after announcing detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer [5]

Group 1: Penguin Solutions, Inc. - Penguin Solutions reported fourth-quarter earnings of 43 cents per share, exceeding the analyst consensus estimate of 38 cents per share [1] - The company reported quarterly sales of $337.922 million, which fell short of the analyst consensus estimate of $342.112 million [1] - For FY2026, Penguin Solutions projects adjusted earnings between $1.75 to $2.25 per share and sales ranging from $1.314 billion to $1.588 billion [2] - Following the earnings report, shares of Penguin Solutions dipped 17.6% to $22.24 in pre-market trading [2] Group 2: Other Companies - Esperion Therapeutics, Inc. saw a decline of 20.1% to $2.47 after announcing a public offering of common stock [4] - NOVONIX Limited experienced a drop of 12.7% to $1.79 after a previous increase of 14% [4] - NANO Nuclear Energy Inc. fell 9.1% to $51.50 following a $400 million oversubscribed private placement of common stock [4] - Joby Aviation, Inc. decreased by 8.5% to $17.30 after pricing a $513.9 million underwritten offering of common shares [4] - Archer Aviation Inc. declined 4.1% to $11.95 after a previous drop of more than 8% [4] - NextNRG Inc. fell 3.2% to $2.73 after a significant increase of 36% the previous day [4] - NuCana plc decreased by 3% to $6.81 in pre-market trading [4]

Group 1: Penguin Solutions, Inc. - Penguin Solutions reported fourth-quarter earnings of 43 cents per share, exceeding the analyst consensus estimate of 38 cents per share [1] - The company reported quarterly sales of $337.922 million, which fell short of the analyst consensus estimate of $342.112 million [1] - For FY2026, Penguin Solutions projects adjusted earnings between $1.75 to $2.25 per share and sales ranging from $1.314 billion to $1.588 billion [2] - Following the earnings report, shares of Penguin Solutions dipped 17.6% to $22.24 in pre-market trading [2] Group 2: Other Companies - Esperion Therapeutics, Inc. saw a decline of 20.1% to $2.47 in pre-market trading after announcing a public offering of common stock [4] - NOVONIX Limited experienced a drop of 12.7% to $1.79 in pre-market trading after a previous increase of 14% [4] - NANO Nuclear Energy Inc. fell 9.1% to $51.50 in pre-market trading due to a $400 million oversubscribed private placement of common stock [4] - Joby Aviation, Inc. decreased by 8.5% to $17.30 in pre-market trading after pricing a $513.9 million underwritten offering of common shares [4] - Archer Aviation Inc. declined 4.1% to $11.95 in pre-market trading after a previous drop of more than 8% [4] - NextNRG Inc. fell 3.2% to $2.73 in pre-market trading after a significant increase of 36% the previous day [4] - NuCana plc decreased by 3% to $6.81 in pre-market trading [4]

Core Viewpoint - Rallybio Corporation (RLYB) shares dropped 41.2% after the company halted the development of RLYB212 due to insufficient pharmacokinetic data from a phase II study [1][2] Group 1: Company Developments - RLYB212 was intended to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT) in pregnant women at risk but failed to meet target concentrations necessary for efficacy [1][2] - Following the setback with RLYB212, the company is now focusing on its lead candidate, RLYB116, which is a differentiated C5 inhibitor aimed at treating complement-driven diseases [4] - Rallybio plans to initiate dosing in a confirmatory pharmacokinetic/pharmacodynamic study for RLYB116 in the second quarter of 2025, targeting diseases such as paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and antiphospholipid syndrome (APS) [5] Group 2: Market Performance - Year to date, Rallybio shares have declined 74%, significantly underperforming the industry, which has seen an 8.9% decline [3] - The management estimates that the market opportunity for complement-mediated diseases like PNH, APS, and gMG exceeds $6 billion [8]